Metastatic melanoma with features of blue nevus and tumoral melanosis identified during pembrolizumab therapy

Matthew F. Helm, Michael J. Bax, Paul N. Bogner, Catherine Chung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Metastatic melanoma may exhibit clinical or histologic features of blue nevus. Pembrolizumab therapy is associated with regression and tumoral melanosis. We report on a man with widespread metastatic melanoma on pembrolizumab therapy in whom a blue-grey papule developed on the left side of his neck that clinically resembled a blue nevus and histologically showed features of both blue nevus and tumoral melanosis. The subtle melanocytic component and prominent changes of regression evident on biopsy suggest that his immunomodulatory therapy may have influenced the histologic findings noted on biopsy. Physicians that treat patients with metastatic melanoma should be aware of the spectrum of histologic findings evident on biopsy not only to allow for early diagnosis but to also better understand the effects of treatment.

Original languageEnglish (US)
Pages (from-to)135-137
Number of pages3
JournalJAAD Case Reports
Volume3
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Blue Nevus
Melanosis
Melanoma
Biopsy
Immunomodulation
Early Diagnosis
Neck
Therapeutics
Physicians
pembrolizumab

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Helm, Matthew F. ; Bax, Michael J. ; Bogner, Paul N. ; Chung, Catherine. / Metastatic melanoma with features of blue nevus and tumoral melanosis identified during pembrolizumab therapy. In: JAAD Case Reports. 2017 ; Vol. 3, No. 2. pp. 135-137.
@article{7c82b51b7b234b6a87c3a5c87e3c1f95,
title = "Metastatic melanoma with features of blue nevus and tumoral melanosis identified during pembrolizumab therapy",
abstract = "Metastatic melanoma may exhibit clinical or histologic features of blue nevus. Pembrolizumab therapy is associated with regression and tumoral melanosis. We report on a man with widespread metastatic melanoma on pembrolizumab therapy in whom a blue-grey papule developed on the left side of his neck that clinically resembled a blue nevus and histologically showed features of both blue nevus and tumoral melanosis. The subtle melanocytic component and prominent changes of regression evident on biopsy suggest that his immunomodulatory therapy may have influenced the histologic findings noted on biopsy. Physicians that treat patients with metastatic melanoma should be aware of the spectrum of histologic findings evident on biopsy not only to allow for early diagnosis but to also better understand the effects of treatment.",
author = "Helm, {Matthew F.} and Bax, {Michael J.} and Bogner, {Paul N.} and Catherine Chung",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.jdcr.2017.01.019",
language = "English (US)",
volume = "3",
pages = "135--137",
journal = "JAAD Case Reports",
issn = "2352-5126",
publisher = "Elsevier Inc.",
number = "2",

}

Metastatic melanoma with features of blue nevus and tumoral melanosis identified during pembrolizumab therapy. / Helm, Matthew F.; Bax, Michael J.; Bogner, Paul N.; Chung, Catherine.

In: JAAD Case Reports, Vol. 3, No. 2, 01.03.2017, p. 135-137.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Metastatic melanoma with features of blue nevus and tumoral melanosis identified during pembrolizumab therapy

AU - Helm, Matthew F.

AU - Bax, Michael J.

AU - Bogner, Paul N.

AU - Chung, Catherine

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Metastatic melanoma may exhibit clinical or histologic features of blue nevus. Pembrolizumab therapy is associated with regression and tumoral melanosis. We report on a man with widespread metastatic melanoma on pembrolizumab therapy in whom a blue-grey papule developed on the left side of his neck that clinically resembled a blue nevus and histologically showed features of both blue nevus and tumoral melanosis. The subtle melanocytic component and prominent changes of regression evident on biopsy suggest that his immunomodulatory therapy may have influenced the histologic findings noted on biopsy. Physicians that treat patients with metastatic melanoma should be aware of the spectrum of histologic findings evident on biopsy not only to allow for early diagnosis but to also better understand the effects of treatment.

AB - Metastatic melanoma may exhibit clinical or histologic features of blue nevus. Pembrolizumab therapy is associated with regression and tumoral melanosis. We report on a man with widespread metastatic melanoma on pembrolizumab therapy in whom a blue-grey papule developed on the left side of his neck that clinically resembled a blue nevus and histologically showed features of both blue nevus and tumoral melanosis. The subtle melanocytic component and prominent changes of regression evident on biopsy suggest that his immunomodulatory therapy may have influenced the histologic findings noted on biopsy. Physicians that treat patients with metastatic melanoma should be aware of the spectrum of histologic findings evident on biopsy not only to allow for early diagnosis but to also better understand the effects of treatment.

UR - http://www.scopus.com/inward/record.url?scp=85015055577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015055577&partnerID=8YFLogxK

U2 - 10.1016/j.jdcr.2017.01.019

DO - 10.1016/j.jdcr.2017.01.019

M3 - Article

C2 - 28367487

AN - SCOPUS:85015055577

VL - 3

SP - 135

EP - 137

JO - JAAD Case Reports

JF - JAAD Case Reports

SN - 2352-5126

IS - 2

ER -